Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.86 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.86 |
| ▸ | CDK2 | P24941 | 7/20 | 0.86 |
| ▸ | CDK1 | P06493 | 3/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.79 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.73 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myoseverin SCHEMBL13325947 | 1.00 | TDP1 (1.00) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL13359693 | 0.95 | TDP1 (0.90) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5461238 | 0.92 | TDP1 (0.86) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL1443236 | 0.89 | TDP1 (0.80) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL4422868 | 0.88 | CDK1 (0.81) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL14587794 | 0.88 | TDP1 (0.78) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL4422862 | 0.88 | CDK1 (0.81) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5466709 | 0.88 | TDP1 (0.78) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL1443401 | 0.87 | CDK1 (0.85) | TDP1CCNE2CCNE1CDK2CDK1 | |
| SCHEMBL5470136 | 0.87 | TDP1 (0.76) | TDP1CCNE2CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| EP-4580677-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4505179-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| US-20240317892-A1 | ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS COMPRISING | JAVELIN ONCOLOGY INC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024050356-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2024-03-07 | — | — | WO | claimed |
| WO-2023215746-A2 | ANTI-ALPPL2 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE | JAVELIN ONCOLOGY, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023212632-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023212646-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023193017-A2 | SARS-COV2 ANTIBODIES AND USES THEREOF | Invivyd, Inc. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023056429-A1 | ANTI-NMDAR2B ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2023-04-06 | — | — | WO | claimed |
| WO-2022170126-A2 | COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF | ADAGIO THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| EP-4731263-A1 | BIO-CONJUGATES FOR ONCOLOGY | RDP Pharma AG (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103506-A1 | SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF | INVIVYD INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260078171-A1 | SARS-COV2 ANTIBODIES AND USES THEREOF | INVIVYD INC (US) | 2026-03-19 | — | — | US | disclosed |
| CN-114099840-A | Point-of-care drug delivery devices and methods | 建南德克公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-107427468-B | Site-specific administration of BTK inhibitors | 普林斯匹亚生物制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317892-A1 | ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS COMPRISING | ADAM12, ADAM10, ADAM17 | TDP1 1103/4885CCNE2 4673/4885CCNE1 4387/4885 |
| US-20260103506-A1 | SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF | IGLV6-57, IGSF11, VSIG8 | TDP1 3791/4885CCNE2 4118/4885CCNE1 4313/4885 |
| US-20260078171-A1 | SARS-COV2 ANTIBODIES AND USES THEREOF | IGLV6-57, SARS1, IGSF11 | TDP1 2252/4885CCNE2 3679/4885CCNE1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.